Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
136-482-Hyaluronoglucosaminidase PH20 (rHuPH20)1件: Hyaluronidase3件: D04455 ,
D04456 ,
D06604 		--1件: 65
2Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20)2件: Daratumumab,
Hyaluronidase (human recombinant)		1件: D10777 1件: CD38 💬7件: Calcium signaling pathway, Hematopoietic cell lineage, Metabolic pathways, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion 💬1件: 28
3Daratumumab coformulato con ialuronidasi umana ricombinante (rHuPH20)1件: Daratumumab1件: D10777 1件: CD38 💬7件: Calcium signaling pathway, Hematopoietic cell lineage, Metabolic pathways, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion 💬1件: 28
4Recombinant Human Hyaluronidase (rHuPH20)2件: Hyaluronidase,
Hyaluronidase (human recombinant)		3件: D04455 ,
D04456 ,
D06604 		--1件: 65
5Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)2件: Hyaluronidase,
Hyaluronidase (human recombinant)		3件: D04455 ,
D04456 ,
D06604 		--1件: 65
6RHuPH20----2件: 13, 14
7SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)----1件: 65
8SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)----1件: 65